BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36875061)

  • 1. Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.
    Chintala NK; Choe JK; McGee E; Bellis R; Saini JK; Banerjee S; Moreira AL; Zauderer MG; Adusumilli PS; Rusch VW
    Front Immunol; 2023; 14():1112960. PubMed ID: 36875061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
    Ekeke CN; Russell KL; Murthy P; Guo ZS; Soloff AC; Weber D; Pan W; Lotze MT; Dhupar R
    J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e313-e328. PubMed ID: 33485667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Manyam M; Stephens AJ; Kennard JA; LeBlanc J; Ahmad S; Kendrick JE; Holloway RW
    Gynecol Oncol; 2021 Dec; 163(3):481-489. PubMed ID: 34686353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
    Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.
    Weibel S; Hofmann E; Basse-Luesebrink TC; Donat U; Seubert C; Adelfinger M; Gnamlin P; Kober C; Frentzen A; Gentschev I; Jakob PM; Szalay AA
    J Transl Med; 2013 May; 11():106. PubMed ID: 23635329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
    Murthy V; Katzman D; Sterman DH
    Clin Respir J; 2019 May; 13(5):272-279. PubMed ID: 30810270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion.
    Li X; Wu G; Chen C; Zhao Y; Zhu S; Song X; Yin J; Lv T; Song Y
    Front Immunol; 2021; 12():760683. PubMed ID: 34966384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.
    Brader P; Kelly KJ; Chen N; Yu YA; Zhang Q; Zanzonico P; Burnazi EM; Ghani RE; Serganova I; Hricak H; Szalay AA; Fong Y; Blasberg RG
    Clin Cancer Res; 2009 Jun; 15(11):3791-801. PubMed ID: 19470726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.
    Lauer UM; Schell M; Beil J; Berchtold S; Koppenhöfer U; Glatzle J; Königsrainer A; Möhle R; Nann D; Fend F; Pfannenberg C; Bitzer M; Malek NP
    Clin Cancer Res; 2018 Sep; 24(18):4388-4398. PubMed ID: 29773661
    [No Abstract]   [Full Text] [Related]  

  • 11. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.
    Minev BR; Lander E; Feller JF; Berman M; Greenwood BM; Minev I; Santidrian AF; Nguyen D; Draganov D; Killinc MO; Vyalkova A; Kesari S; McClay E; Carabulea G; Marincola FM; Butterfield LH; Szalay AA
    J Transl Med; 2019 Aug; 17(1):271. PubMed ID: 31426803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
    Belin LJ; Ady JW; Lewis C; Marano D; Gholami S; Mojica K; Eveno C; Longo V; Zanzonico PB; Chen NG; Szalay AA; Fong Y
    Surgery; 2013 Sep; 154(3):486-95. PubMed ID: 23890748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic herpesvirus therapy for mesothelioma - A phase I/IIa trial of intrapleural administration of HSV1716.
    Danson SJ; Conner J; Edwards JG; Blyth KG; Fisher PM; Muthana M; Salawu A; Taylor F; Hodgkinson E; Joyce P; Roman J; Simpson K; Graham A; Learmonth K; Woll PJ
    Lung Cancer; 2020 Dec; 150():145-151. PubMed ID: 33160198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.
    Iankov ID; Msaouel P; Allen C; Federspiel MJ; Bulur PA; Dietz AB; Gastineau D; Ikeda Y; Ingle JN; Russell SJ; Galanis E
    Breast Cancer Res Treat; 2010 Aug; 122(3):745-54. PubMed ID: 19894113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.
    Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
    Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
    J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study.
    Choi MG; Park S; Oh DK; Kim HR; Lee GD; Lee JC; Choi CM; Ji W
    Thorac Cancer; 2019 Oct; 10(10):1885-1892. PubMed ID: 31389192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrapleural Anticancer Therapy for Malignant Pleural Diseases: Facts or Fiction?
    Agrawal A; Chaddha U; Shojaee S; Maldonado F
    Semin Respir Crit Care Med; 2023 Aug; 44(4):462-467. PubMed ID: 37308112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.